|
|
|
| Serum inflammatory Factors Vascular Endothelial Function and Pulmonary Function of Ulinastatin Combined with Ipratropium Bromide in the Treatment of AECOPD |
| LONG Shenghua, et al |
| The Central Hospital of Huangshi of Edong Medical Group, Hubei Huangshi 435000, China |
|
|
|
|
Abstract Objective: To observe the efficacy and effect on serum inflammatory factors, vascular endothelial function and pulmonary function of ulinastatin combined with ipratropium bromide in the treatment of AECOPD. Methods: 125 cases of patients with AECOPD were randomly divided into observation group (64 cases) and control group (61 cases).The control group were given ipratropium bromide based on conventional therapy,and the observation group were given ulinastatin based on the control group. After 1 week ,to observe the clinical efficacy and differences of serum inflammatory factors (hs-CRP, TNF-α, IL-1, IL-8), vascular endothelial function related indicators (ET-1, NO, TXB2, VEGF), and pulmonary function (TLC, PEF1, PEF25, PEF50) between the two group. Results: ①Comparison of curative efficacy the observation group, excellence got 32 cases, effective got 32 cases,invalid 4 cases failure,and those of the control group was 18 cases,37 cases and 6 cases. The clinical efficacy of the two groups showed significant difference(Z=-2.123 P=0.034); ②Comparison of serum inflammatory factors, and all indexs of the observation group improved more significantly than that of the control group, with statistical difference (t=5.419,5.184,4.893,7.241 P=0.000,0.002,0.006,0.000); ③Comparison of vascular endothelial function. The two groups of NO, VEGF were decreased and ET-1,TXB2 were decreased, and all indexs of the observation group improved more significantly than that of the control group, with statistical difference (t=9.182,18.831,6.271,11.382 P=0.000,0.000,0.000,0.000);④Comparison of vascular pulmonary function. The two groups of TLC, PEF1, PEF25, PEF50 were increased with before, and all the indexs of the observation group improved more significantly than that of the control group, with statistical difference (t=5.402, 4.927, 4.238, 5.701 P=0.009, 0.011, 0.019, 0.003). Conclusion: Ulinastatin combined with ipratropium bromide is effective in the treatment of AECOPD, which can effectively inhibit the inflammatory reaction, protect the vascular endothelial function and lung function.
|
|
|
|
|
|
[1] 徐佩枫,陈玉玲.慢性阻塞性肺病急性加重伴肺栓塞的危险因素[J].临床肺科杂志,2017,22(08):1375~1379.
[2] 张飔雪.乌司他丁治疗慢性阻塞性肺疾病急性加重期患者的效果观察[J].实用临床医药杂志,2016,20(13):32~35.
[3] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2013年修订版)[J].中华结核和呼吸杂志,2013,36(4):255~264.
[4] 倪晓辉,朱萍,刘云杰,等.中性粒细胞CD64指数在慢性阻塞性肺疾病急性加重期细菌感染中的诊断价值[J].中华全科医学,2016,14(11):1889~1891.
[5] 王秋颖,郭晓慧,徐丹丹.慢性阻塞性肺疾病急性加重期合并2型糖尿病患者血降钙素原、超敏C反应蛋白水平变化[J].中国老年学杂志,2016,36(20):5076~5077.
[6] 张杰,张颖,余其贵,等.老年慢性阻塞性肺疾病急性发作患者血清中血管内皮因子变化及其意义[J].安徽医药,2014,18(01):109~112.
[7] 陶广华,张文龙,刘向六,等.右美托咪定联合乌司他丁对单肺通气肺癌患者血清促炎因子水平的影响[J].山东医药,2017,57(37):48~51.
[8] 任宪军.乌司他丁对肝癌术后感染性休克患者TNF-α、hs-CRP水平的影响及疗效评估[J].实用癌症杂志,2017,32(12):1937~1939.
[9] 朱利明,李琦,潘晓骅.异丙托溴铵联合布地奈德对慢性阻塞性肺疾病患者肺功能及血清相关指标的影响[J].国际检验医学杂志,2017,38(08):1100~1102. |
|
|
|
2018, Vol. 24 
